Literature DB >> 7850555

Age as a prognostic factor in the malignant melanoma population.

P F Austin1, C W Cruse, G Lyman, K Schroer, F Glass, D S Reintgen.   

Abstract

BACKGROUND: The incidence of malignant melanoma is increasing faster than any other cancer, and the state of Florida has one of the highest incidence of melanoma in the United States. This increased incidence is thought to be due to the intense sunlight exposure and ultraviolet radiation exposure in the elderly population. With the increased emphasis on issues of aging, it is appropriate to study the role of age as a prognostic factor for malignant melanoma in the Florida population.
METHODS: A retrospective, computer-aided search identified 442 consecutively registered patients with malignant melanoma at the Cutaneous Oncology Program. All patients had stage 1 or 2 disease (cutaneous disease only) at diagnosis. Prognostic variables analyzed included the most powerful factors for stage 1 and 2 melanoma, tumor thickness, ulceration, and Clark level of invasion. Other prognostic variables included in the analysis were the clinical variables of sex and primary site (axial vs. extremity). The population was divided into patients < or = 65 and > 65 years of age.
RESULTS: Significant disease-free survival differences were encountered in the older population, with only 55% of the elderly population being disease free at 5 years compared with 65% for the younger population (p = 0.0073). However, a greater percentage of patients with melanoma who were > 65 years of age had ulcerated lesions (17.5% vs. 12.9%) and a greater percentage of thick lesions at diagnosis (67.2% vs. 62.7%). Both of these prognostic factors would bias the older population with a poorer survival. A stepwise regression analysis of the entire population was performed, treating age as a continuous variable. Surprisingly, increasing age along with tumor thickness were the only significant predictors for disease-free survival. After inclusion of these two prognostic variables, none of the other prognostic factors, including Clark level, ulceration, sex, and primary site, added to the prognostic model.
CONCLUSIONS: From this analysis, it is apparent that geriatric patients with melanoma have a worse prognosis than a younger control population, even after the correction for the more commonly cited prognostic factors. This information should be used in mathematical modeling to identify high-risk populations who are candidates for perhaps more aggressive primary or adjuvant therapies.

Entities:  

Mesh:

Year:  1994        PMID: 7850555     DOI: 10.1007/bf02303614

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Epidemiology and prognostic factors in malignant melanoma.

Authors:  D S Rigel
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

2.  Recurrent malignant melanoma: the identification of prognostic factors to predict survival.

Authors:  D S Reintgen; C Cox; C L Slingluff; H F Seigler
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

3.  Isolated limb perfusion for recurrent melanoma of the extremity.

Authors:  D S Reintgen; C W Cruse; K E Wells; H I Saba; C L Slingluff
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

4.  Melanoma in people aged 65 and over in Scotland, 1979-89.

Authors:  P M McHenry; D J Hole; R M MacKie
Journal:  BMJ       Date:  1992-03-21

5.  Immunology and aging Philip Levine Award.

Authors:  R L Walford
Journal:  Am J Clin Pathol       Date:  1980-09       Impact factor: 2.493

Review 6.  Aging and neoplasia.

Authors:  J Crawford; H J Cohen
Journal:  Annu Rev Gerontol Geriatr       Date:  1984

7.  Correlation of thicknesses of superficial spreading malignant melanomas and ages of patients.

Authors:  J Levine; A W Kopf; D S Rigel; R S Bart; P Hennessey; R J Friedman; M M Mintzis
Journal:  J Dermatol Surg Oncol       Date:  1981-04

8.  Invasive cutaneous melanoma in elderly patients.

Authors:  B Loggie; S G Ronan; J Bean; T K Das Gupta
Journal:  Arch Dermatol       Date:  1991-08

9.  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial.

Authors:  C M Balch; M M Urist; C P Karakousis; T J Smith; W J Temple; K Drzewiecki; W R Jewell; A A Bartolucci; M C Mihm; R Barnhill
Journal:  Ann Surg       Date:  1993-09       Impact factor: 12.969

10.  Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease.

Authors:  F L Meyskens; D H Berdeaux; B Parks; T Tong; L Loescher; T E Moon
Journal:  Cancer       Date:  1988-09-15       Impact factor: 6.860

View more
  28 in total

1.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Demographic and other characteristics of nodal non-Hodgkin's lymphoma managed in academic versus non-academic centers.

Authors:  Vijaya Raj Bhatt; Prajwal Dhakal; Sumit Dahal; Smith Giri; Ranjan Pathak; R Gregory Bociek; Peter T Silberstein; James O Armitage
Journal:  Ther Adv Hematol       Date:  2015-10

3.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

4.  Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma.

Authors:  Mario Mandalà; Gian Lorenzo Imberti; Dario Piazzalunga; Maurizio Belfiglio; Giuseppe Lucisano; Roberto Labianca; Lorenzo Marchesi; Barbara Merelli; Silvana Robone; Paola Poletti; Laura Milesi; Carlo Tondini
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

5.  Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.

Authors:  Xiaofan Lu; Qianyuan Zhang; Yue Wang; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Tao Lu; Fei Wang; Fangrong Yan
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-11       Impact factor: 4.553

Review 6.  Epidemiology and treatment of melanoma in elderly patients.

Authors:  Susan Tsai; Charles Balch; Julie Lange
Journal:  Nat Rev Clin Oncol       Date:  2010-02-09       Impact factor: 66.675

7.  Impact of age on the management of primary melanoma patients.

Authors:  Nathaniel H Fleming; Jiaying Tian; Eleazar Vega-Saenz de Miera; Heidi Gold; Farbod Darvishian; Anna C Pavlick; Russell S Berman; Richard L Shapiro; David Polsky; Iman Osman
Journal:  Oncology       Date:  2013-08-30       Impact factor: 2.935

8.  Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.

Authors:  Aminah Jatoi; Jacob B Allred; Vera J Suman; Edward T Creagan; Gary A Croghan; Thomas Amatruda; Svetomir N Markovic
Journal:  J Geriatr Oncol       Date:  2012-05-07       Impact factor: 3.599

9.  Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base.

Authors:  Vijaya Raj Bhatt; Rajesh Shrestha; Jairam Krishnamurthy; Kailash Mosalpuria; Fausto R Loberiza; Apar Kishor Ganti; Peter T Silberstein
Journal:  Ther Adv Med Oncol       Date:  2015-01       Impact factor: 8.168

10.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.